SG11202104051VA - Miniaturized dystrophins and uses thereof - Google Patents

Miniaturized dystrophins and uses thereof

Info

Publication number
SG11202104051VA
SG11202104051VA SG11202104051VA SG11202104051VA SG11202104051VA SG 11202104051V A SG11202104051V A SG 11202104051VA SG 11202104051V A SG11202104051V A SG 11202104051VA SG 11202104051V A SG11202104051V A SG 11202104051VA SG 11202104051V A SG11202104051V A SG 11202104051VA
Authority
SG
Singapore
Prior art keywords
dystrophins
miniaturized
miniaturized dystrophins
Prior art date
Application number
SG11202104051VA
Inventor
Glen Banks
Jonathan Harry Davis
Paul Charles Levesque
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of SG11202104051VA publication Critical patent/SG11202104051VA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SG11202104051VA 2018-10-24 2019-10-24 Miniaturized dystrophins and uses thereof SG11202104051VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862749982P 2018-10-24 2018-10-24
PCT/US2019/057855 WO2020086844A1 (en) 2018-10-24 2019-10-24 Miniaturized dystrophins and uses thereof

Publications (1)

Publication Number Publication Date
SG11202104051VA true SG11202104051VA (en) 2021-05-28

Family

ID=68582390

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202104051VA SG11202104051VA (en) 2018-10-24 2019-10-24 Miniaturized dystrophins and uses thereof

Country Status (16)

Country Link
US (1) US20210403947A1 (en)
EP (1) EP3870202A1 (en)
JP (1) JP2022505816A (en)
KR (1) KR20210082193A (en)
CN (1) CN113613668A (en)
AU (1) AU2019368307A1 (en)
BR (1) BR112021007480A2 (en)
CA (1) CA3117738A1 (en)
CL (1) CL2021000994A1 (en)
CO (1) CO2021005083A2 (en)
EA (1) EA202191123A1 (en)
IL (1) IL282547A (en)
MX (1) MX2021004688A (en)
PE (1) PE20211110A1 (en)
SG (1) SG11202104051VA (en)
WO (1) WO2020086844A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021222332A1 (en) 2020-04-29 2021-11-04 Bristol-Myers Squibb Company Miniaturized dystrophins having spectrin fusion domains and uses thereof
WO2022023284A1 (en) 2020-07-27 2022-02-03 Anjarium Biosciences Ag Compositions of dna molecules, methods of making therefor, and methods of use thereof
US20240003898A1 (en) * 2020-10-30 2024-01-04 Pfizer Inc. Methods for measuring dystrophin in tissue samples
WO2022241030A1 (en) * 2021-05-11 2022-11-17 Regenxbio Inc. Treatment of duchenne muscular dystrophy and combinations thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
EP1366160B1 (en) 2000-10-06 2008-07-09 The Regents Of The University Of Michigan Mini-dystrophin nucleic acid and peptide sequences
TWI290174B (en) 2002-11-04 2007-11-21 Advisys Inc Synthetic muscle promoters with activities exceeding naturally occurring regulatory sequences in cardiac cells
US10479821B2 (en) * 2015-01-16 2019-11-19 University Of Washington Micro-dystrophins and related methods of use
CA2971303A1 (en) * 2016-06-21 2017-12-21 Bamboo Therapeutics, Inc. Optimized mini-dystrophin genes and expression cassettes and their use

Also Published As

Publication number Publication date
JP2022505816A (en) 2022-01-14
CO2021005083A2 (en) 2021-04-30
IL282547A (en) 2021-06-30
CN113613668A (en) 2021-11-05
EP3870202A1 (en) 2021-09-01
AU2019368307A1 (en) 2021-06-10
CA3117738A1 (en) 2020-04-30
US20210403947A1 (en) 2021-12-30
MX2021004688A (en) 2021-06-04
KR20210082193A (en) 2021-07-02
WO2020086844A1 (en) 2020-04-30
BR112021007480A2 (en) 2021-08-10
PE20211110A1 (en) 2021-06-17
EA202191123A1 (en) 2022-03-29
CL2021000994A1 (en) 2021-09-20

Similar Documents

Publication Publication Date Title
IL273236A (en) Pyrazolopyrimidinone compounds and uses thereof
IL293377A (en) Hsd17b13 variants and uses thereof
EP4076448A4 (en) Fluoroalkyl-oxadiazoles and uses thereof
GB201803568D0 (en) Novel compounds and uses
IL268593A (en) Polypeptide variants and uses thereof
IL282547A (en) Miniaturized dystrophins and uses thereof
GB201808566D0 (en) Improved device and components thereof
IL280808A (en) Ox40-binding polypeptides and uses thereof
EP3728294A4 (en) Insecticidal polypeptides and uses thereof
IL277502A (en) Compounds and uses thereof
SG11202006669RA (en) Peptides and uses thereof
IL279483A (en) Cyanotriazole compounds and uses thereof
GB201819200D0 (en) Polypeptide and uses thereof
IL280644A (en) Magnesium-serinate compound and use thereof
GB201812561D0 (en) Biomarkers and uses thereof
IL273048A (en) Melanin antibodies and uses thereof
GB201806042D0 (en) Biomarkers and uses thereof
EP3480212C0 (en) Il13ralpha2 peptide and its uses
IL273671A (en) Cornulin (crnn) variants and uses thereof
IL269836B (en) Substituted n-arylethyl-2-aminoquinoline-4-carboxamides and use thereof
EP3684796A4 (en) Succinate-regulating polypeptides and use thereof
IL280369A (en) New myokines and uses thereof
GB202114111D0 (en) Assembly and device thereof
IL269843B (en) Substituted n-arylethyl-2-arylquinoline-4-carboxamides and use thereof
GB201819125D0 (en) Biomarkers and uses thereof